Amarin Corp Plcuk (AMRN) Change in Accured Expenses (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Change in Accured Expenses of -$15.4 million for Q2 2026, down 165.63% year-over-year from $23.5 million in Q2 2025, and down 4.28% quarter-over-quarter from -$14.8 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Change in Accured Expenses for 17 consecutive years, with -$15.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Accured Expenses fell 165.63% year-over-year to -$15.4 million; the TTM figure through Jun 2026 stood at -$21.8 million (up 51.23% YoY), while the FY2025 annual figure was $14.5 million, up 118.85% from the prior year.
- Change in Accured Expenses declined to -$15.4 million in Q2 2026 per AMRN's latest filing, from -$14.8 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $61.0 million in Q2 2022 and bottomed at -$69.7 million in Q1 2022.
- Historically, Change in Accured Expenses has averaged -$10.9 million across 5 years, with a median of -$15.0 million in 2023.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 1175.14% — and 2025, when it surged 176.85%.
- Amarin Corp Plc\Uk's Change in Accured Expenses stood at -$28.1 million in 2022, then jumped by 73.09% to -$7.6 million in 2023, then slumped by 186.16% to -$21.6 million in 2024, then jumped by 156.59% to $12.2 million in 2025, then tumbled by 226.36% to -$15.4 million in 2026.
- Business Quant data shows AMRN's Change in Accured Expenses at -$15.4 million in Q2 2026, -$14.8 million in Q1 2026, and $12.2 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.32 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.20 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 852.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 338.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | -15.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.45 Mn |
| Jun 30, 2026 | -15.45 Mn |
| Mar 31, 2026 | -14.82 Mn |
| Mar 31, 2026 | -14.82 Mn |
| Dec 31, 2025 | 12.23 Mn |
| Dec 31, 2025 | 12.23 Mn |
| Sep 30, 2025 | -3.71 Mn |
| Sep 30, 2025 | -3.71 Mn |
| Jun 30, 2025 | 23.54 Mn |
| Jun 30, 2025 | 23.54 Mn |
| Mar 31, 2025 | -17.54 Mn |
| Mar 31, 2025 | -17.54 Mn |
| Dec 31, 2024 | -21.61 Mn |
| Dec 31, 2024 | -21.61 Mn |
| Sep 30, 2024 | -28.99 Mn |
| Sep 30, 2024 | -28.99 Mn |
| Jun 30, 2024 | 8.50 Mn |
| Jun 30, 2024 | 8.50 Mn |
| Mar 31, 2024 | -34.90 Mn |
| Mar 31, 2024 | -34.90 Mn |